Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2011-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study 16 Patients diagnosed with Nonarteritic Anterior Ischemic Optic Neuropathy(NSION) who had a sudden mono ocular vision loss associated with optic disc edema and positive Marcus Gunn in less than 30 days without exclusion criteria are randomly divided in two groups 1) control 2) case. In case group Avastin and Triamcinolone will be injected trough vitreal and placebo will be injected in control group. BCVA and Visual field will be then measured in these two groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO)

NCT00370630

Retinovascular Disease

UNKNOWN PHASE2

Intravitreal Triamcinolone for Acute Branch Retinal Vein Occlusion

NCT00370266

Branch Retinal Vein Occlusion

COMPLETED PHASE2

To Compare Therapeutic Effect of Intravitreal Bevacizumab and Triamcinolone in Resistant Uveitic Cystoid Macular Edema

NCT00371111

Resistant Cystoid Macular Edema

UNKNOWN PHASE1

Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD

NCT00370370

Neovascular Age-Related Macular Degeneration

UNKNOWN PHASE3

Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion

NCT01044329

Branch Retinal Vein Occlusion

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Nonarteritic Anterior Ischemic Optic Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Avastin and Triamcinolone

Group Type ACTIVE_COMPARATOR

Avastin and Triamcinolone

Intervention Type DRUG

1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal

Placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

2mg placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Avastin and Triamcinolone

1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal

Intervention Type DRUG

placebo

2mg placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Sudden mono ocular vision loss associated with optic disc edema and positive Marcus Gunn (\<30 days)

Exclusion Criteria

* Any eye disease except NAION(Nonarteritic Anterior Ischemic Optic Neuropathy)
* Neurologic defect
* Abnormal ESR, CRP, any history of retina or vitreal surgery
* Severe corneal opacity which makes retina examination impossible

Eligible Sex

ALL

Accepts Healthy Volunteers

No